Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0VCYEK
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HuAD208.14.1-vcMMAE-DAR4
|
|||||
| Synonyms |
HuAD208.14.1 vcMMAE-DAR4; huAD208.14.1 vcMMAE-DAR4
Click to Show/Hide
|
|||||
| Organization |
AbbVie, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Non-small cell lung cancer [ICD11:2C25]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
huAD208.14.1
|
Antibody Info | ||||
| Antigen Name |
Leucine-rich repeat-containing protein 15 (LRRC15)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 90.12% (Day 21) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huAD208.14.1-vcMMAE-DAR4 (3 mg/kg) was demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.